1. Johns L.E., Houlston R.S. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001; 96(10): 2992 - 3003.

2. Tenesa A., Dunlop M.G. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 2009; 10(6): 353 - 8.

3. Huxley R.R., Ansary-Moghaddam A., Clifton P., Czernichow S., Parr C.L., Woodward M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer 2009; 125(1): 171 - 80.

4. Rasool S., Kadla S.A., Rasool V., Ganai B.A. A comparative overview of general risk factors associated with the incidence of colorectal cancer. Tumour Biol 2013; 34(5): 2469 - 76.

5. Raskov H., Pommergaard H.C., Burcharth J., Rosenberg J. Colorectal carcinogenesis - update and perspectives. World J Gastroenterol 2014; 20(48): 18151 - 64.

6. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: ФГБУ "МНИОИ им. П.А. Герцена" Минздрава России. 2017. 250 с.

7. WHO Classification of Tumours Editorial Board. Digestive system tumors (5th ed). IARC; Lyon, 2019.

8. Group M.S. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 2007; 243(1): 132 - 9.

9. Glynne-Jones R., Wyrwicz L., Tiret E., Brown G., C., Cervantes A., Arnold D. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2018.

10. Holland-Frei Cancer Medicine Cloth. Bast Jr R.C., Croce C.M., Hait W.N., Hong W.K., Kufe D.W., Piccart-Gebart M., Pollock R.E., Weichselbaum R.R., Wang H., Holland J.F. John Wiley & Sons, 2017.

11. Steele S.R., Hull T.L., Read T.E., Saclarides T.J., Senagore A.J., Whitlow C.B. The ASCRS textbook of colon and rectal surgery. Springer, 2016.

12. Malik S.S., Lythgoe M.P., McPhail M., Monahan K.J. Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis. Familial cancer 2018; 17(4): 557 - 564.

13. van Erp S.J., Leicher L.W., Hennink S.D., Ghorbanoghli Z., Breg S.A., Morreau H., Nielsen M., Hardwick J.C., Roukema J.A., Langers A.M. Identification of familial colorectal cancer and hereditary colorectal cancer syndromes through the Dutch population-screening program: results of a pilot study. Scandinavian journal of gastroenterology 2016; 51(10): 1227 - 32.

14. Syngal S., Fox E.A., Eng C., Kolodner R.D., Garber J.E. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 2000; 37(9): 641 - 5.

15. Цуканов А.С., Шелыгин Ю.А., Ачкасов С.И., Фролов С.А., Кашников В.Н., Кузьминов А.М., и др. Принципы диагностики и персонифицированного лечения наследственных форм колоректального рака. Вестн. Росс. акад. мед. наук 2019; 74(2): 118 - 24.

16. Liu Z., Zhang Y., Niu Y., Li K., Liu X., Chen H., Gao C. A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer. PLoS One 2014; 9(8): e103910.

17. Tanaka A., Sadahiro S., Suzuki T., Okada K., Saito G. Comparisons of Rigid Proctoscopy, Flexible Colonoscopy, and Digital Rectal Examination for Determining the Localization of Rectal Cancers. Dis Colon Rectum 2018; 61(2): 202 - 6.

18. Chong A., Shah J.N., Levine M.S., Rubesin S.E., Laufer I., Ginsberg G.G., Long W.B., Kochman M.L. Diagnostic yield of barium enema examination after incomplete colonoscopy. Radiology 2002; 223(3): 620 - 4.

19. Pickhardt P.J., Hassan C., Halligan S., Marmo R. Colorectal cancer: CT colonography and colonoscopy for detection - systematic review and meta-analysis. Radiology 2011; 259(2): 393 - 405.

20. Kim J.H., Kim W.H., Kim T.I., Kim N.K., Lee K.Y., Kim M.J., Kim K.W. Incomplete colonoscopy in patients with occlusive colorectal cancer: usefulness of CT colonography according to tumor location. Yonsei Med J 2007; 48(6): 934 - 41.

21. Neri E., Giusti P., Battolla L., Vagli P., Boraschi P., Lencioni R., Caramella D., Bartolozzi C. Colorectal cancer: role of CT colonography in preoperative evaluation after incomplete colonoscopy. Radiology 2002; 223(3): 615 - 9.

22. Langevin J.M., Nivatvongs S. The true incidence of synchronous cancer of the large bowel. A prospective study. Am J Surg 1984; 147(3): 330 - 3.

23. Mulder S.A., Kranse R., Damhuis R.A., de Wilt J.H., Ouwendijk R.J., Kuipers E.J., van Leerdam M.E. Prevalence and prognosis of synchronous colorectal cancer: a Dutch population-based study. Cancer Epidemiol 2011; 35(5): 442 - 7.

24. Martling A., Holm T., Bremmer S., Lindholm J., Cedermark B., Blomqvist L. Prognostic value of preoperative magnetic resonance imaging of the pelvis in rectal cancer. Br J Surg 2003; 90(11): 1422 - 8.

25. Algebally A.M., Mohey N., Szmigielski W., Yousef R.R., Kohla S. The value of high-resolution MRI technique in patients with rectal carcinoma: pre-operative assessment of mesorectal fascia involvement, circumferential resection margin and local staging. Pol J Radiol 2015; 80: 115 - 21.

26. Norenberg D., Sommer W.H., Thasler W., D'Haese J., Rentsch M., Kolben T., Schreyer A., Rist C., Reiser M., Armbruster M. Structured Reporting of Rectal Magnetic Resonance Imaging in Suspected Primary Rectal Cancer: Potential Benefits for Surgical Planning and Interdisciplinary Communication. Invest Radiol 2017; 52(4): 232 - 239.

27. Battersby N.J., How P., Moran B., Stelzner S., West N.P., Branagan G., Strassburg J., Quirke P., Tekkis P., Pedersen B.G., Gudgeon M., Heald B., Brown G., Group M.I.S. Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model: The MERCURY II Study. Ann Surg 2016; 263(4): 751 - 60.

28. Sahni V.A., Silveira P.C., Sainani N.I., Khorasani R. Impact of a Structured Report Template on the Quality of MRI Reports for Rectal Cancer Staging. AJR Am J Roentgenol 2015; 205(3): 584 - 8.

29. Vliegen R.F., Beets G.L., von Meyenfeldt M.F., Kessels A.G., Lemaire E.E., van Engelshoven J.M., Beets-Tan R.G. Rectal cancer: MR imaging in local staging - is gadolinium-based contrast material helpful? Radiology 2005; 234(1): 179 - 88.

30. Floriani I., Torri V., Rulli E., Garavaglia D., Compagnoni A., Salvolini L., Giovagnoni A. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging 2010; 31(1): 19 - 31.

31. Schmoll H.J., Van Cutsem E., Stein A., Valentini V., Glimelius B., Haustermans K., et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making. Ann Oncol 2012; 23(10): 2479 - 516.

32. Niekel M.C., Bipat S., Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010; 257(3): 674 - 84.

33. Choi S.H., Kim S.Y., Park S.H., Kim K.W., Lee J.Y., Lee S.S., Lee M.G. Diagnostic performance of CT, gadoxetate disodium-enhanced MRI, and PET/CT for the diagnosis of colorectal liver metastasis: Systematic review and meta-analysis. J Magn Reson Imaging 2018; 47(5): 1237 - 50.

34. Ko Y., Kim J., Park J.K.-H., Kim H., Cho J.Y., Kang S.-B., et al. Limited detection of small (<= 10 mm) colorectal liver metastasis at preoperative CT in patients undergoing liver resection. PloS One 2017; 12(12): e0189797.

35. Lazzaron A., Vieira M., Damin D. Should preoperative chest computed tomography be performed in all patients with colorectal cancer? Colorectal Disease 2015; 17(10): O184 - O190.

36. Herrmann J., Lerman A., Sandhu N.P., Villarraga H.R., Mulvagh S.L., Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc 2014; 89(9): 1287 - 306.

37. Starck M., Bohe M., Simanaitis M., Valentin L. Rectal endosonography can distinguish benign rectal lesions from invasive early rectal cancers. Colorectal Dis 2003; 5(3): 246 - 50.

38. Santoro G.A., Gizzi G., Pellegrini L., Battistella G., Di Falco G. The value of high-resolution three-dimensional endorectal ultrasonography in the management of submucosal invasive rectal tumors. Dis Colon Rectum 2009; 52(11): 1837 - 43.

39. Zorcolo L., Fantola G., Cabras F., Marongiu L., D'Alia G., Casula G. Preoperative staging of patients with rectal tumors suitable for transanal endoscopic microsurgery (TEM): comparison of endorectal ultrasound and histopathologic findings. Surg Endosc 2009; 23(6): 1384 - 9.

40. Roth E.S., Fetzer D.T., Barron B.J., Joseph U.A., Gayed I.W., Wan D.Q. Does colon cancer ever metastasize to bone first? a temporal analysis of colorectal cancer progression. BMC cancer 2009; 9(1): 274.

41. Augestad K.M., Bakaki P.M., Rose J., Crawshaw B.P., Lindsetmo R.O., Dorum L.M., Koroukian S.M., Delaney C.P. Metastatic spread pattern after curative colorectal cancer surgery. A retrospective, longitudinal analysis. Cancer Epidemiol 2015; 39(5): 734 - 44.

42. Daza J.F., Solis N.M., Parpia S., Gallinger S., Moulton C.A., Belley-Cote E.P., Levine M.N., Serrano P.E. A meta-analysis exploring the role of PET and PET-CT in the management of potentially resectable colorectal cancer liver metastases. Eur J Surg Oncol 2019; 45(8): 1341 - 8.

43. Muntean V., Oniu T., Lungoci C., Fabian O., Munteanu D., Molnar G., Bintintan V. Staging laparoscopy in digestive cancers. J Gastrointestin Liver Dis 2009; 18(4): 461 - 7.

44. De Marco M.F., Janssen-Heijnen M.L., van der Heijden L.H., Coebergh J.W. Comorbidity and colorectal cancer according to subsite and stage: a population-based study. Eur J Cancer 2000; 36(1): 95 - 9.

45. Khattak M.A., Martin H., Davidson A., Phillips M. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials. Clin Colorectal Cancer 2015; 14(2): 81 - 90.

46. Pietrantonio F., Petrelli F., Coinu A., Di Bartolomeo M., Borgonovo K., Maggi C., Cabiddu M., Iacovelli R., Bossi I., Lonati V., Ghilardi M., de Braud F., Barni S. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51(5): 587 - 94.

47. Prasad V., Kaestner V., Mailankody S. Cancer drugs approved based on biomarkers and not tumor type - FDA approval of pembrolizumab for mismatch repair-deficient solid cancers. JAMA oncology 2018; 4(2): 157 - 158.

48. Therkildsen C., Bergmann T.K., Henrichsen-Schnack T., Ladelund S., Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol 2014; 53(7): 852 - 64.

49. Jasperson K.W., Tuohy T.M., Neklason D.W., Burt R.W. Hereditary and familial colon cancer. Gastroenterology 2010; 138(6): 2044 - 58.

50. Medina Pabon M.A., Babiker H.M. A Review Of Hereditary Colorectal Cancers. StatPearls. Treasure Island (FL), 2019.

51. Wada H., Shiozawa M., Katayama K., Okamoto N., Miyagi Y., Rino Y., Masuda M., Akaike M. Systematic review and meta-analysis of histopathological predictive factors for lymph node metastasis in T1 colorectal cancer. J Gastroenterol 2015; 50(7): 727 - 34.

52. Beaton C., Twine C.P., Williams G.L., Radcliffe A.G. Systematic review and meta-analysis of histopathological factors influencing the risk of lymph node metastasis in early colorectal cancer. Colorectal Dis 2013; 15(7): 788 - 97.

53. Siddiqui M.R.S., Simillis C., Bhoday J., Battersby N.J., Mok J., Rasheed S., Tekkis P., Abulafi A.M., Brown G. A meta-analysis assessing the survival implications of subclassifying T3 rectal tumours. Eur J Cancer 2018; 104: 47 - 61.

54. Guerra G.R., Kong C.H., Warrier S.K., Lynch A.C., Heriot A.G., Ngan S.Y. Primary squamous cell carcinoma of the rectum: An update and implications for treatment. World J Gastrointest Surg 2016; 8(3): 252 - 65.

55. Vyas N., Ahmad S., Bhuiyan K., Catalano C., Alkhawam H., Sogomonian R., Nguyen J., Walfish A., Aron J. Primary squamous cell carcinoma of the rectum: a case report and literature review. J Community Hosp Intern Med Perspect 2016; 6(3): 31708.

56. Sturgeon J.D., Crane C.H., Krishnan S., Minsky B.D., Skibber J.M., Rodriguez-Bigas M.A., Chang G.J., You Y.N., Eng C., Das P. Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. Am J Clin Oncol 2017; 40(2): 163 - 166.

57. Babaei M., Jansen L., Balavarca Y., Sjovall A., Bos A., van de Velde T., et al. Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes. Clin Colorectal Cancer 2018; 17(1): e129 - e142.

58. Abraha I., Aristei C., Palumbo I., Lupattelli M., Trastulli S., Cirocchi R., De Florio R., Valentini V. Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma. Cochrane Database Syst Rev 2018; 10: CD002102.

59. Sager O., Dincoglan F., Demiral S., Uysal B., Gamsiz H., Dirican B., Beyzadeoglu M. A Concise Review of Pelvic Radiation Therapy (RT) for Rectal Cancer with Synchronous Liver Metastases. Int J Surg Oncol 2019; 2019:5239042.

60. Kim M.J., Kim S.J., Park S.C., Kim D.Y., Park J.W., Ryoo S.B., Jeong S.Y., Park K.J., Oh H.K., Kim D.W., Kang S.B., Joo J.N., Oh J.H., Group S.E.C. Adjuvant radiotherapy for the treatment of stage IV rectal cancer after curative resection: A propensity score-matched analysis and meta-analysis. Medicine (Baltimore) 2016; 95(47): e4925.

61. Liu Q., Shan Z., Luo D., Cai S., Li Q., Li X. Palliative beam radiotherapy offered real-world survival benefit to metastatic rectal cancer: A large US population-based and propensity score-matched study. J Cancer 2019; 10(5): 1216 - 1225.

62. De Caluwe L., Van Nieuwenhove Y., Ceelen W.P. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2013. doi: 10.1002/14651858.CD006041.pub3; 2: CD006041.

63. Latkauskas T., Pauzas H., Gineikiene I., Janciauskiene R., Juozaityte E., Saladzinskas Z., Tamelis A., Pavalkis D. Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery. Colorectal Dis 2012; 14(3): 294 - 8.

64. Hofheinz R.D., Wenz F., Post S., Matzdorff A., Laechelt S., Hartmann J.T., et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012; 13(6): 579 - 88.

65. O'Connell M.J., Martenson J.A., Wieand H.S., Krook J.E., Macdonald J.S., Haller D.G., Mayer R.J., Gunderson L.L., Rich T.A. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331(8): 502 - 7.

66. McCarthy K., Pearson K., Fulton R., Hewitt J. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev 2012; 12: CD008368.

67. Ngan S.Y., Burmeister B., Fisher R.J., Solomon M., Goldstein D., Joseph D., et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012; 30(31): 3827 - 33.

68. Du D., Su Z., Wang D., Liu W., Wei Z. Optimal Interval to Surgery After Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Systematic Review and Meta-analysis. Clin Colorectal Cancer 2018; 17(1): 13 - 24.

69. Petrelli F., Sgroi G., Sarti E., Barni S. Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies. Ann Surg 2016; 263(3): 458 - 64.

70. Lefevre J.H., Mineur L., Kotti S., Rullier E., Rouanet P., de Chaisemartin C., et al. Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6). J Clin Oncol 2016; 34(31): 3773 - 80.

71. Marco M.R., Zhou L., Patil S., Marcet J.E., Varma M.G., Oommen S., et al. Timing of Rectal Cancer Response to Chemoradiation C. Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. Dis Colon Rectum 2018; 61(10): 1146 - 55.

72. Kim S.Y., Joo J., Kim T.W., Hong Y.S., Kim J.E., Hwang I.G., et al. A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03. Int J Radiat Oncol Biol Phys 2018; 101(4): 889 - 99.

73. Liang H.Q., Dong Z.Y., Liu Z.J., Luo J., Zeng Q., Liao P.Y., Wu D.H. Efficacy and safety of consolidation chemotherapy during the resting period in patients with local advanced rectal cancer. Oncol Lett 2019; 17(2): 1655 - 63.

74. Pettersson D., Cedermark B., Holm T., Radu C., Pahlman L., Glimelius B., Martling A. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 2010; 97(4): 580 - 7.

75. van der Valk M.J.M., Hilling D.E., Bastiaannet E., Meershoek-Klein Kranenbarg E., Beets G.L., Figueiredo N.L., Habr-Gama A., Perez R.O., Renehan A.G., van de Velde C.J.H., Consortium I. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 2018; 391(10139): 2537 - 45.

76. Dossa F., Chesney T.R., Acuna S.A., Baxter N.N. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2017; 2(7): 501 - 513.

77. Cercek A., Roxburgh C.S.D., Strombom P., Smith J.J., Temple L.K.F., Nash G.M., et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol 2018; 4(6): e180071.

78. Zhang J., Hu H., Cai Y., Chen D., Xiao J., Ling J., Deng Y. Total neoadjuvant treatment versus chemoradiotherapy in locally advanced rectal cancer: A propensity score analysis from two prospective phase II clinical trials. Book Editor American Society of Clinical Oncology 2018.

79. Mathis K.L., Nelson H., Pemberton J.H., Haddock M.G., Gunderson L.L. Unresectable colorectal cancer can be cured with multimodality therapy. Annals of surgery 2008; 248(4): 592 - 598.

80. Minsky B.D., Cohen A.M., Kemeny N., Enker W.E., Kelsen D.P., Saltz L., Frankel J. The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. Cancer 1993; 71(11): 3486 - 92.

81. Minsky B.D., Cohen A.M., Enker W.E., Saltz L., Guillem J.G., Paty P.B., Kelsen D.P., Kemeny N., Ilson D., Bass J., Conti J. Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. Int J Radiat Oncol Biol Phys 1997; 37(2): 289 - 95.

82. van der Pas M.H., Haglind E., Cuesta M.A., Furst A., Lacy A.M., Hop W.C., Bonjer H.J., Group C.O.c.L.o.O.R.I.S. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol 2013; 14(3): 210 - 8.

83. Jeong S.Y., Park J.W., Nam B.H., Kim S., Kang S.B., Lim S.B., et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol 2014; 15(7): 767 - 74.

84. Green B.L., Marshall H.C., Collinson F., Quirke P., Guillou P., Jayne D.G., Brown J.M. Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. Br J Surg 2013; 100(1): 75 - 82.

85. Schwenk W., Haase O., Neudecker J., Muller J.M. Short term benefits for laparoscopic colorectal resection. Cochrane Database Syst Rev 2005.10.1002/14651858.CD003145.pub2 N 3): CD003145.

86. Breukink S., Pierie J., Wiggers T. Laparoscopic versus open total mesorectal excision for rectal cancer. Cochrane Database Syst Rev 2006.10.1002/14651858.CD005200.pub2 N 4): CD005200.

87. Ribas Y., Hotouras A., Wexner S.D., D'Hoore A. Shared decision-making and informed consent process in rectal cancer treatment: weighing up oncological and functional outcomes. Colorectal Dis 2016; 18(1): 9 - 12.

88. Chude G.G., Rayate N.V., Patris V., Koshariya M., Jagad R., Kawamoto J., Lygidakis N.J. Defunctioning loop ileostomy with low anterior resection for distal rectal cancer: should we make an ileostomy as a routine procedure? A prospective randomized study. Hepatogastroenterology 2008; 55(86 - 87): 1562 - 7.

89. Гордеев С., Иванов В., Расулов А., Барсуков Ю., Ткачев С., Сураева Ю., Черных М., Кузьмичев Д., Козак Е., Малихов А. Химиолучевая терапия осложненного местнораспространенного и рецидивного рака прямой кишки. Медицинская радиология и радиационная безопасность 2016; 61(6): 57 - 63.

90. Nascimbeni R., Nivatvongs S., Larson D.R., Burgart L.J. Long-term survival after local excision for T1 carcinoma of the rectum. Dis Colon Rectum 2004; 47(11): 1773 - 9.

91. Sgourakis G., Lanitis S., Gockel I., Kontovounisios C., Karaliotas C., Tsiftsi K., Tsiamis A., Karaliotas C.C. Transanal endoscopic microsurgery for T1 and T2 rectal cancers: a meta-analysis and meta-regression analysis of outcomes. Am Surg 2011; 77(6): 761 - 72.

92. Doornebosch P.G., Tollenaar R.A., De Graaf E.J. Is the increasing role of Transanal Endoscopic Microsurgery in curation for T1 rectal cancer justified? A systematic review. Acta Oncol 2009; 48(3): 343 - 53.

93. Taylor F.G., Quirke P., Heald R.J., Moran B., Blomqvist L., Swift I., Sebag-Montefiore D.J., Tekkis P., Brown G., group M.s. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg 2011; 253(4): 711 - 9.

94. Cho S.H., Choi G.S., Kim G.C., Seo A.N., Kim H.J., Kim W.H., Shin K.M., Lee S.M., Ryeom H., Kim S.H. Long-term outcomes of surgery alone versus surgery following preoperative chemoradiotherapy for early T3 rectal cancer: A propensity score analysis. Medicine (Baltimore) 2017; 96(12): e6362.

95. Richardson B., Preskitt J., Lichliter W., Peschka S., Carmack S., de Prisco G., Fleshman J. The effect of multidisciplinary teams for rectal cancer on delivery of care and patient outcome: has the use of multidisciplinary teams for rectal cancer affected the utilization of available resources, proportion of patients meeting the standard of care, and does this translate into changes in patient outcome? Am J Surg 2016; 211(1): 46 - 52.

96. Allard M.A., Adam R., Giuliante F., Lapointe R., Hubert C., Ijzermans J.N.M., et al. Long-term outcomes of patients with 10 or more colorectal liver metastases. Br J Cancer 2017; 117(5): 604 - 611.

97. Adam R., Wicherts D.A., de Haas R.J., Ciacio O., F., Paule B., Ducreux M., Azoulay D., Bismuth H., Castaing D. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure. J Clin Oncol 2009; 27(11): 1829 - 1835.

98. Wang J., Luo L., Wang D., Guo B., Li J., Yang Z., Tang D. Combination adjuvant chemotherapy with targeted drugs for treatment of colorectal cancer: A network meta-analysis. J Cell Biochem 2018; 119(2): 1521 - 1537.

99. Brandi G., De Lorenzo S., Nannini M., Curti S., Ottone M., Dall'Olio F.G., Barbera M.A., Pantaleo M.A., Biasco G. Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. World J Gastroenterol 2016; 22(2): 519 - 33.

100. Modest D.P., Martens U.M., Riera-Knorrenschild J., Greeve J., Florschutz A., Wessendorf S., et al. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). J Clin Oncol 2019.10.1200/JCO.19.01340): JCO1901340.

101. Федянин М., Трякин А., Тюляндин С. Потенциальные предикторы эффективности анти-EGFR-терапии при метастатическом раке толстой кишки. Онкологическая колопроктология 2013; 2.

102. Cetinkaya E., Dogrul A.B., Tirnaksiz M.B. Role of self expandable stents in management of colorectal cancers. World J Gastrointest Oncol 2016; 8(1): 113 - 20.

103. Nielsen M.B., Laurberg S., Holm T. Current management of locally recurrent rectal cancer. Colorectal Dis 2011; 13(7): 732 - 42.

104. Rahbari N.N., Ulrich A.B., Bruckner T., Munter M., Nickles A., Contin P., Loffler T., Reissfelder C., Koch M., Buchler M.W., Weitz J. Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure? Ann Surg 2011; 253(3): 522 - 33.

105. Lee J.H., Kim D.Y., Kim S.Y., Park J.W., Choi H.S., Oh J.H., Chang H.J., Kim T.H., Park S.W. Clinical outcomes of chemoradiotherapy for locally recurrent rectal cancer. Radiat Oncol 2011; 6: 51.

106. Tanis P.J., Doeksen A., van Lanschot J.J. Intentionally curative treatment of locally recurrent rectal cancer: a systematic review. Can J Surg 2013; 56(2): 135 - 44.

107. Bird T.G., Ngan S.Y., Chu J., Kroon R., Lynch A.C., Heriot A.G. Outcomes and prognostic factors of multimodality treatment for locally recurrent rectal cancer with curative intent. Int J Colorectal Dis 2018; 33(4): 393 - 401.

108. Watanabe J., Shoji H., Hamaguchi T., Miyamoto T., Hirano H., Iwasa S., Honma Y., Takashima A., Kato K., Ito Y., Itami J., Kanemitsu Y., Boku N. Chemoradiotherapy for Local Recurrence of Rectal Cancer: A Single Center Study of 18 Patients. In Vivo 2019; 33(4): 1363 - 1368.

109. Yu S.K., Bhangu A., Tait D.M., Tekkis P., Wotherspoon A., Brown G. Chemoradiotherapy response in recurrent rectal cancer. Cancer Med 2014; 3(1): 111 - 7.

110. Guren M.G., Undseth C., Rekstad B. L., Braendengen M., Dueland S., Spindler K.L., Glynne-Jones R., Tveit K.M. Reirradiation of locally recurrent rectal cancer: a systematic review. Radiother Oncol 2014; 113(2): 151 - 7.

111. Petrelli F., Coinu A., Lonati V., Barni S. A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer. Int J Colorectal Dis 2015; 30(4): 447 - 57.

112. Andre T., Colin P., Louvet C., Gamelin E., Bouche O., Achille E., Colbert N., Boaziz C., Piedbois P., Tubiana-Mathieu N., Boutan-Laroze A., Flesch M., Billiau V., Buyse M., Gramont A., Groupe d'Etude et de Recherche Clinique en Oncologie R. Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies. Semin Oncol 2001; 28(1) Suppl 1: 35 - 40.

113. Breugom A.J., van Gijn W., Muller E.W., Berglund A., van den Broek C.B., Fokstuen T., Gelderblom H., Kapiteijn E., Leer J.W., Marijnen C.A., Martijn H., Meershoek-Klein Kranenbarg E., Nagtegaal I.D., Pahlman L., Punt C.J., Putter H., Roodvoets A.G., Rutten H.J., Steup W.H., Glimelius B., van de Velde C.J., Cooperative Investigators of Dutch Colorectal Cancer G., Nordic Gastrointestinal Tumour Adjuvant Therapy G. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo) radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol 2015; 26(4): 696 - 701.

114. Guo Y., Xiong B.H., Zhang T., Cheng Y., Ma L. XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis. Cancer Invest 2016; 34(2): 94 - 104.

115. Kato T., Nagata N., Fujii M., Takemoto H., Kondo K., Okuyama Y., Tominaga H., Sakamoto J., Mishima H. Multi-center phase II study of FLOX for advanced colorectal cancer patients in Japan: SWIFT 3 study. Anticancer Res 2011; 31(12): 4657 - 64.

116. Andre T., Quinaux E., Louvet C., Colin P., Gamelin E., Bouche O., et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 2007; 25(24): 3732 - 8.

117. Mizushima T., Ikeda M., Kato T., Ikeda A., Nishimura J., Hata T., Matsuda C., Satoh T., Mori M., Doki Y. Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study. BMC Cancer 2019; 19(1): 929.

118. Федянин М., Трякин А., Тюляндин С. Адъювантная химиотерапия после химиолучевого лечения рака прямой кишки. Онкологическая колопроктология 2014; 2.

119. Seymour M.T., Maughan T.S., Ledermann J.A., Topham C., James R., Gwyther S.J., Smith D.B., Shepherd S., Maraveyas A., Ferry D.R., Meade A.M., Thompson L., Griffiths G.O., Parmar M.K., Stephens R.J., Investigators F.T., National Cancer Research Institute Colorectal Clinical Studies G. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370(9582): 143 - 152.

120. Cunningham D., Sirohi B., Pluzanska A., Utracka-Hutka B., Zaluski J., Glynne-Jones R., Koralewski P., Bridgewater J., Mainwaring P., Wasan H. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol 2008; 20(2): 244 - 50.

121. Ackland S.P., Jones M., Tu D., Simes J., Yuen J., Sargeant A.M., Dhillon H., Goldberg R.M., Abdi E., Shepherd L., Moore M.J. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Br J Cancer 2005; 93(11): 1236 - 43.

122. Baraniskin A., Buchberger B., Pox C., Graeven U., Holch J.W., Schmiegel W., Heinemann V. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. Eur J Cancer 2019; 106: 37 - 44.

123. Rosa B., de Jesus J.P., de Mello E.L., Cesar D., Correia M.M. Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis. eCancerMedicalScience 2015; 9: 582.

124. Le D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372(26): 2509 - 20.

125. Overman M.J., McDermott R., Leach J.L., Lonardi S., Lenz H.J., Morse M.A., et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017; 18(9): 1182 - 91.

126. Overman M.J., Lonardi S., Wong K.Y.M., Lenz H.J., Gelsomino F., Aglietta M., et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol 2018; 36(8): 773 - 9.

127. Le D.T., Kim T.W., Van Cutsem E., Geva R., Jager D., Hara H., et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol 2019.10.1200/JCO.19.02107): JCO1902107.

128. Cremolini C., Loupakis F., Antoniotti C., Lupi C., Sensi E., Lonardi S., Mezi S., Tomasello G., Ronzoni M., Zaniboni A. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. The Lancet Oncology 2015; 16(13): 1306 - 15.

129. Pratyaksha W., Valentina P., Ben V., Peter K., Evaristo M., Mark J.G., Curca R.-O.D., Meinolf K., Bridgewater J.A., Mihailov A.C. VELOUR trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity. Ann Oncol 2017; 28.

130. Kopetz S., McDonough S.L., Morris V.K., Lenz H.-J., Magliocco A.M., Atreya C.E., Diaz L.A., Allegra C.J., Wang S.E., Lieu C.H. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). Book Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). Editor American Society of Clinical Oncology 2017.

131. Corcoran R.B., Andre T., Atreya C.E., Schellens J.H.M., Yoshino T., Bendell J.C., et al. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer. Cancer Discov 2018; 8(4): 428 - 43.

132. Vieitez J.M., Carrasco J., Esteban E., Fra J., Alvarez E., Muniz I., Sala M., Buesa J.M., Jimenez Lacave A. Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with Fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage. Am J Clin Oncol 2003; 26(2): 107 - 11.

133. Bayraktar B., Ozemir I.A., Kefeli U., Demiral G., J., Bayraktar O., Adali G., Ozcelik A., Tortum O.B. Colorectal stenting for palliation and as a bridge to surgery: A 5-year follow-up study. World Journal of Gastroenterology: WJG 2015; 21(31): 9373.

134. Cameron M.G., Kersten C., Vistad I., S., Guren M.G. Palliative pelvic radiotherapy of symptomatic incurable rectal cancer - a systematic review. Acta Oncologica 2014; 53(2): 164 - 73.

135. Costi R., Leonardi F., Zanoni D., Violi V., Roncoroni L. Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist. World Journal of Gastroenterology: WJG 2014; 20(24): 7602.

136. Silver J.K., Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. American journal of physical medicine & rehabilitation 2013; 92(8): 715 - 27.

137. Greer N.L., Gunnar W.P., Dahm P., Lee A.E., MacDonald R., Shaukat A., Sultan S., Wilt T.J. Enhanced Recovery Protocols for Adults Undergoing Colorectal Surgery: A Systematic Review and Meta-analysis. Dis Colon Rectum 2018; 61(9): 1108 - 18.

138. Hijazi Y., Gondal U., Aziz O. A systematic review of prehabilitation programs in abdominal cancer surgery. Int J Surg 2017; 39:156 - 62.

139. Gillis C., Li C., Lee L., Awasthi R., Augustin B., Gamsa A., Liberman A.S., Stein B., Charlebois P., Feldman L.S., Carli F. Prehabilitation versus rehabilitation: a randomized control trial in patients undergoing colorectal resection for cancer. Anesthesiology 2014; 121(5): 937 - 47.

140. Tsimopoulou I., Pasquali S., Howard R., Desai A., Gourevitch D., Tolosa I., Vohra R. Psychological prehabilitation before cancer surgery: a systematic review. Annals of surgical oncology 2015; 22(13): 4117 - 23.

141. Li P., Fang F., Cai J.X., Tang D., Li Q.G., Wang D.R. Fast-track rehabilitation vs conventional care in laparoscopic colorectal resection for colorectal malignancy: a meta-analysis. World J Gastroenterol 2013; 19(47): 9119 - 26.

142. Wren S.M., Martin M., Yoon J.K., Bech F. Postoperative pneumonia-prevention program for the inpatient surgical ward. J Am Coll Surg 2010; 210(4): 491 - 5.

143. de Almeida E.P.M., de Almeida J.P., Landoni G., Galas F., Fukushima J.T., Fominskiy E., et al. Early mobilization programme improves functional capacity after major abdominal cancer surgery: a randomized controlled trial. Br J Anaesth 2017; 119(5): 900 - 7.

144. Visser W.S., Te Riele W.W., Boerma D., van Ramshorst B., van Westreenen H.L. Pelvic floor rehabilitation to improve functional outcome after a low anterior resection: a systematic review. Ann Coloproctol 2014; 30(3): 109 - 14.

145. Efthimiadis C., Basdanis G., Zatagias A., Tzeveleki I., Kosmidis C., Karamanlis E., Harlaftis N. Manometric and clinical evaluation of patients after low anterior resection for rectal cancer. Techniques in coloproctology 2004; 8(1): s205 - s207.

146. Finnane A., Janda M., Hayes S.C. Review of the evidence of lymphedema treatment effect. Am J Phys Med Rehabil 2015; 94(6): 483 - 98.

147. Cheville A.L., Kollasch J., Vandenberg J., Shen T., Grothey A., Gamble G., Basford J.R. A home-based exercise program to improve function, fatigue, and sleep quality in patients with Stage IV lung and colorectal cancer: a randomized controlled trial. J Pain Symptom Manage 2013; 45(5): 811 - 21.

148. Jeon J., Sato K., Niedzwiecki D., Ye X., Saltz L.B., Mayer R.J., et al. Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 2013; 12(4): 233 - 8.

149. Mosher C.E., Winger J.G., Given B.A., Helft P.R., O'Neil B.H. Mental health outcomes during colorectal cancer survivorship: a review of the literature. Psychooncology 2016; 25(11): 1261 - 70.

150. Mustian K.M., Alfano C.M., Heckler C., Kleckner A.S., Kleckner I.R., Leach C.R., et al. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis. JAMA Oncol 2017; 3(7): 961 - 8.

151. Kinkead B., Schettler P.J., Larson E.R., Carroll D., Sharenko M., Nettles J., Edwards S.A., Miller A.H., Torres M.A., Dunlop B.W., Rakofsky J.J., Rapaport M.H. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Cancer 2018; 124(3): 546 - 54.

152. Bensadoun R.J., Nair R.G. Low-Level Laser Therapy in the Management of Mucositis and Dermatitis Induced by Cancer Therapy. Photomed Laser Surg 2015; 33(10): 487 - 91.

153. Pita-Fernandez S., Alhayek-Ai M., Gonzalez-Martin C., Lopez-Calvino B., Seoane-Pillado T., Pertega-Diaz S. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. Ann Oncol 2015; 26(4): 644 - 56.

154. Jeffery M., Hickey B.E., Hider P.N. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2007. doi: 10.1002/14651858.CD002200.pub2 N 1): CD002200.

155. Zech C., et al. Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases. Br J Surg 2014. Vol. 101. N 6. P. 613 - 621.9.

156. Xin-Yu Wang, Zhi-Xue Zheng, Yu Sun, Yan-Hua Bai, Yun-Fei Shi, Li-Xin Zhou, et al. Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas. World J Gastrointest Oncol 2019; 11(4): 335 - 47. doi: 10.4251/wjgo.v11.i4.335.

157. Funda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, Robert R McWilliams, Marwan Fakih, Ari VanderWalde, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2019; 20(4): 518 - 530. doi: 10.1016/S1470-2045(18)30904-5.

158. Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, Katia Bencardino, Sara Lonardi, Francesca Bergamo, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17(6): 738 - 46. doi: 10.1016/S1470-2045(16)00150-9.

159. Qiang Li, Ying Liu, Hong-Mei Zhang, Yin-Peng Huang, Tian-Yi Wang, Dong-Sheng Li, et al. Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis, Gastroenterology Research and Practice, vol. 2014, Article ID 827989, 11 pages, 2014.

160. Lugli A., Kirsch R., Ajioka Y., et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol 2017; 30(9): 1299 - 311.

161. Клинические рекомендации. Хронический болевой синдром (ХБС) у взрослых пациентов, нуждающихся в паллиативной медицинской помощи. МЗ РФ. 2018.

162. Nilsson P.J., et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer - the RAPIDO trial. BMC cancer 2013. Т. 13. N. 1. P. 1 - 9.

163. Jin J., et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). Journ Clin Oncol 2022. С. JCO. 21.01667.

164. Petrelli F. et al. Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann Surg 2020. Т. 271. N 3. 440 - 448.

165. Riesco-Martinez Maria C., et al. Impact of Total Neoadjuvant Therapy vs. Standard Chemoradiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. Cancers 12.12 (2020): 3655.

166. Melissa Amy Lumish, Jenna L. Cohen, Zsofia Kinga Stadler, et al. PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer. Journal of Clinical Oncology 40, no. 4_suppl (February 01, 2022) 16 - 16.

167. Wang L., et al. Early versus late closure of temporary ileostomy after rectal cancer surgery: a meta-analysis. Surgery Today 2020. С. 1 - 9.

168. Elsner A.T., et al. Closure of Temporary Ileostomy 2 Versus 12 Weeks After Rectal Resection for Cancer: A Word of Caution From a Prospective, Randomized Controlled Multicenter Trial // Dis Col Rect 2021 Т. 64. N 11. P. 1398.

169. Park J., et al. Cost analysis in a randomized trial of early closure of a temporary ileostomy after rectal resection for cancer (EASY trial). Surgical endoscopy. 2020. Т. 34. N 1. Р. 69 - 76.

170. Danielsen A.K. et al. Early closure of a temporary ileostomy in patients with rectal cancer. Ann Surg 2017. Т. 265. N 2. P. 284 - 90.

171. Kye B.H., et al. Is it safe the reversal of a diverting stoma during adjuvant chemotherapy in elderly rectal cancer patients? International Journal of Surgery 2014. Т. 12. N 12. P. 1337 - 41.

172. Hajibandeh S., et al. Meta-analysis of temporary loop ileostomy closure during or after adjuvant chemotherapy following rectal cancer resection: the dilemma remains. International journal of colorectal disease. 2019. Т. 34. N 7. P. 1151 - 59.

173. Overman M.J. et al. Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142. 2017.

174. Thierry , Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis Punt, Denis Smith, Rocio Garcia-Carbonero, Manuel Benavides, Peter Gibbs, Christelle de la Fouchardiere, Fernando Rivera, Elena Elez, Johanna Bendell, Dung T Le, Takayuki Yoshino, Eric Van Cutsem, Ping Yang, Mohammed Z H Farooqui, Patricia Marinello, Luis A Diaz Jr, KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020 Dec 3; 383(23): 2207 - 18. doi: 10.1056/NEJMoa2017699.

175. Heinz-Josef Lenz, Sara Lonardi, Vittorina Zagonel, Eric Van Cutsem, M. Luisa Limon, Ka Yeung Mark Wong, et al. Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update. Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 3521 - 3521. doi: 10.1200/JCO.2019.37.15_suppl.3521.

176. Brandi G., et al. Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. World journal of gastroenterology. 2016. Т. 22. N 2. P. 519.

177. Andre T., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109 - 16.

178. Kuebler JP, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198 - 204.

179. McCleary NJ, et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 2013; 31: 2600 - 6.

180. Cheeseman S.L., Joel S.P., Chester J.D., et al. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002; 87(4): 393 - 9. DOI: 10.1038/sj.bjc.6600467.

181. Matsumoto S. et al. Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. Chemotherapy. 2008. Т. 54. N 5. P. 395 - 403.

182. Cassidy J. et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. Journal of Clinical Oncology. 2004. Т. 22. N 11. P. 2084 - 91.

183. L Demir 1, I Somali, M Oktay Tarhan, C Erten, H Ellidokuz, A Can, A Dirican, I Vedat Bayoglu. The toxicity and efficacy of Nordic-FLOX regimen as adjuvant treatment of stage III colon cancer. J BUON. Oct-Dec 2011; 16(4): 682 - 8.

184. Sorbye H, Glimelius B, Berglund A et al. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004; 22: 31 - 38.

185. Трякин А.А., Бесова Н.С., Волков Н.М., Гладков С.А., Карасева В.В., Сакаева Д.Д. Практические рекомендации по общим принципам проведения противоопухолевой лекарственной терапии. Злокачественные опухоли. Практические рекомендации RUSSCO#3s2, 2020; 10: 01.

186. Yukihide Kanemitsu, Kohei Shitara, Junki Mizusawa, Tetsuya Hamaguchi, Dai Shida, Koji Komori, et al. A randomized phase III trial comparing primary tumor resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 study (iPACS). Journal of Clinical Oncology 38, no. 4_suppl (February 01, 2020) 7 - 7. doi: 10.1200/JCO.2020.38.4_suppl.7.

187. Kanemitsu Y. et al. Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic, synchronous unresectable metastases (JCOG1007; iPACS): a randomized clinical trial. Journal of Clinical Oncology. 2021. Т. 39. N 10. P. 1098 - 107.

188. Matsuda A., et al. Comparison between biweekly and weekly cetuximab in patients with metastatic colorectal cancer: a meta-analysis. Anticancer Research. 2020. Т. 40. N 6. P. 3469 - 76.

189. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212).

190. Bendell J.C., et al. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. Clin Colorect Cancer. 2013. Т. 12. N 4. P. 239 - 47.

191. Aparicio T., et al. Bevacizumab + chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: A randomized phase II trial - PRODIGE 20 study results. Ann Oncol 2018. Т. 29. N 1. P. 133 - 8.

192. Verdaguer H., Tabernero J., Macarulla T. Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Therapeutic advances in medical oncology. 2016. Т. 8. N 3. P. 230 - 42.

193. Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015; 16(5): 499 - 508.

194. Folprecht G., et al. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study Ann Oncol 2016. Т. 27. N 7. P. 1273 - 9.

195. Koukourakis G.V., et al. Capecitabine for locally advanced and metastatic colorectal cancer: A review. World journal of gastrointestinal oncology 2010. Т. 2. N 8. P. 311.

196. Petrioli R., et al. FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. Oncology. 2006. Т. 70. N 5. - P. 345 - 50.

197. Feliu J. et al. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Brit J Cancer 2010. Т. 102. N 10. P. 1468 - 73.

198. Динаева Э.А., и др. Значение эмпегфилграстима в интенсивных режимах терапии опухолей ЖКТ. Доклад на сессии отечественные исследования в онкологии, конференции "Опухоли ЖКТ" 15 апреля 2022 г. https://www.sciencedirect.com/science/article/pii/S2468294221001623. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189469/.

199. Jaafar Bennouna, Sandrine Hiret, Aurelie Bertaut, Olivier , Gael Deplanque, Christian Borel, et al. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. JAMA Oncol 2019; 5(1): 83 - 90. doi: 10.1001/jamaoncol.2018.4465.

200. J Randolph Hecht, Allen Cohn, Shaker Dakhil, Mansoor Saleh, Bilal Piperdi, Mika Cline-Burkhardt, Ying Tian, William Y Go. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2015 Jun; 14(2): 72 - 80. doi: 10.1016/j.clcc.2014.12.009.

201. Romain Cohen, Aurelia Meurisse, Thomas Pudlarz, et al. One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study. Journal of Clinical Oncology 40, no. 4_suppl (February 01, 2022) 13 - 13.

202. Федянин М.Ю., Полянская Е.М., Трякин А.А., и др. Влияние стартовой дозы регорафениба на общую выживаемость пациентов с метастатическим раком толстой кишки: систематический обзор и метаанализ. Современная онкология 2019. Т. 21. N 3. С. 10 - 15. doi: 10.26442/18151434.2019.3.190651.

203. Funda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, Robert R McWilliams, Marwan Fakih, Ari VanderWalde, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2019 Apr; 20(4): 518 - 530. doi: 10.1016/S1470-2045(18)30904-5.

204. Overman M.J., et al. Nivolumab+/-ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. 2016.

205. Osman , Muhammet Bekir , Abdullah Sakin, Demir, Murat , Ozlem Ozkul, et al. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer? Cancer Chemother Pharmacol 2019; 83(1): 115 - 22. doi: 10.1007/s00280-018-3713-6.

206. Gundgaard M.G., Soerensen J.B., Ehrnrooth E. Third-line therapy for metastatic colorectal cancer // Cancer chemotherapy and pharmacology 2008. Т. 61. N 1. P. 1 - 13.

207. Walter T., et al. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. Journal of cancer research and clinical oncology 2020. Т. 146. N 10. P. 2575 - 87.

208. Федянин М.Ю., Полянская Е.М., Эльснукаева Х.Х., Трякин А.А., Покатаев И.А., Буланов А.А., Тюляндин С.А. Метаанализ исследований по сравнению эффективности режимов FOLFOXIRI и FOLFOX или FOLFIRI с таргетной терапией при метастатическом раке толстой кишки с мутацией в гене BRAF. Медицинский Совет 2020; (20): 125 - 132. https://doi.org/10.21518/2079-701X-2020-20-125-132.

209. Wirapati P., Pomella V., Vandenbosch B. et al. Velour trial biomarkers update: impact of RAS, BRAF, and sidedness on aflibercept activity. J Clin Oncol 2017; (15 Suppl): 3538.

210. Gong J., Cho M., Fakih M. RAS and BRAF in metastatic colorectal cancer management // Journal of gastrointestinal oncology. 2016. Т. 7. N 5. P. 687.

211. Bekaii-Saab T.S., et al. Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study. J Clin Oncol 2018. Т. 36. N 4 Suppl. P. 611.

212. Trullas A. et al. The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer //ESMO open. 2021. Т. 6. N 3. P. 100145.

213. Lenz H.J., Lonardi S., Zagonel V. et al. Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update. J Clin Oncol 2019; 37(15 Suppl): 3521. doi: 10.1200/JCO.2019.37.15_suppl.3521.

214. Kanat O., Ertas H. Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy. World Journal of Clinical Oncology 2019. Т. 10. N 2. P. 52.

215. Wu Z. et al. BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF (V600E)-mutant colorectal cancer cells // Acta Biochimica et Biophysica Sinica 2018. Т. 50. N 4. P. 355 - 61.

216. M. Fedyanin1, H. Elsnukaeva1, I. Demidova, et al. 448P - Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practice. Annals of Oncology (2021) 32 (suppl_5): S530 - S582. doi: 10.1016/annonc/annonc698.

217. Corcoran R.B. et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. Cancer discovery. - 2018. - Т. 8. - N. 4. - P. 428 - 443.

218. Yaeger R. et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clinical cancer research 2015. Т. 21. N 6. P. 1313 - 20.

219. Hyman D.M. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. New England Journal of Medicine 2015. Т. 373. N 8. С. 726 - 736.

220. Владимирова Л.Ю.. и др. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных. Злокачественные опухоли 2021. Т. 11. N 3 s2 - 2. С. 25 - 38.

221. Багрова С.Г., и др. Использование остеомодифицирующих агентов (ОМА) для профилактики и лечения патологии костной ткани при злокачественных новообразованиях. Злокачественные опухоли 2021. Т. 10. N 3 s2 - 2. С. 35 - 44.

222. Сакаева Д.Д. и др. Практические рекомендации по диагностике и лечению фебрильной нейтропении. Злокачественные опухоли 2021. Т. 11. N 3 s2 - 2. С. 55 - 63.

223. Ткаченко П.Е., Ивашкин В.Т., Маевская М.В. Клинические рекомендации по коррекции гепатотоксичности, индуцированной противоопухолевой терапией. Злокачественные опухоли 2021. Т. 10. N 3 s2 - 2. С. 52 - 65.

224. Виценя М.В., и др. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии. Злокачественные опухоли 2021. Т. 10. N 3 s2 - 2. С. 66 - 87.

225. Королева И.А., и др. Практические рекомендации по лекарственному лечению дерматологических реакций у пациентов, получающих противоопухолевую лекарственную терапию. Злокачественные опухоли 2021. Т. 11. N 3 S2 - 2. С. 99 - 113.

226. Сытов А.В., и др. Практические рекомендации по нутритивной поддержке онкологических больных. Злокачественные опухоли. 2021. Т. 11. N 3 s2 - 2. С. 114 - 22.

227. Громова Е.Г., и др. Практические рекомендации по коррекции нефротоксичности противоопухолевых препаратов. Злокачественные опухоли 2021. Т. 11. N 3 s2 - 2. С. 132 - 44.

228. Сомонова О.В., и др. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных. Злокачественные опухоли 2021. Т. 11. N 3 S2 - 2. С. 145 - 55.

229. Буйденок Ю.В. Рекомендации по лечению последствий экстравазации противоопухолевых препаратов. Злокачественные опухоли 2021. Т. 10. N 3 s2 - 2. С. 141 - 7.

230. Проценко С.А., и др. Практические рекомендации по управлению иммуноопосредованными нежелательными явлениями. Злокачественные опухоли 2021. Т. 11. N 3 s2 - 2. С. 187 - 223.

231. Анемия при злокачественных новообразованиях. Клинические рекомендации МЗ РФ. Электронный ресурс: https://cr.minzdrav.gov.ru/schema/624_1. Дата обращения 23.05.2022 г.

232. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., Carbone P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5(6): 649 - 55.

233. Karnofsky D.A., Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C. (ed.). Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949: 191 - 205.

234. Hawker G.A., Mian S., Kendzerska T., French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 2011; 63 (Suppl 11): S240 - 52.

235. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.